Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT03933670 | Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance | recruiting | Phase 2 | 60 | University of California, San FranciscoOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06083844 | Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05255653 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features(RAINBO) | recruiting | Phase 2 / Phase 3 | 1,615 | Leiden University Medical CenterOTHER | 4 | May 15, 2026 | clinicaltrials |
| NCT07476001 | Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC | recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589543 | Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer(EB-DUALNK-OV) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05413850 | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | recruiting | Phase 1 / Phase 2 | 82 | Blue Earth Therapeutics LtdINDUSTRY | 5 | May 14, 2026 | clinicaltrials |
| NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors(N01-A-PICIT-GT) | recruiting | Phase 2 | 220 | Peking University People's HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | recruiting | Phase 2 | 300 | RenJi HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05284552 | Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer | recruiting | Phase 2 | 40 | University Hospital, LinkoepingOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05903833 | Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy(PIERCE) | recruiting | Phase 2 | 42 | AGO Research GmbHINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT05979610 | Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies(Reiki-Brachy) | recruiting | Phase 2 | 70 | University of UtahOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07571551 | Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma(TRIPLE-PATH) | recruiting | Phase 2 | 75 | Jinling Hospital, ChinaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04986423 | ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 200 | Zenith EpigeneticsINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT05363280 | Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment | recruiting | Phase 2 | 80 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT07087860 | Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers(RECIPE-B1) | recruiting | Phase 2 | 70 | Mayo ClinicOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07384416 | QL1706 Plus Lenvatinib in Previously Treated Penile Cancer | recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07414940 | ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium(ACT-RESoLUTE) | recruiting | Phase 1 / Phase 2 | 60 | University College, LondonOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06023862 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)(DOVE) | recruiting | Phase 2 | 198 | Yonsei UniversityOTHER | 7 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06266338 | Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix) | recruiting | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06822010 | SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma | recruiting | Phase 2 | 28 | Rutgers, The State University of New JerseyOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05125016 | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 228 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT06616155 | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07354919 | Axelopran for Advanced Cancer in Patients Receiving Opioids(AxeCan) | recruiting | Phase 2 | 34 | HealthPartners InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05551507 | IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03067051 | Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System | recruiting | Phase 1 / Phase 2 | 66 | SpectraCure ABINDUSTRY | 4 | May 1, 2026 | clinicaltrials |
| NCT06807359 | Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System | recruiting | Phase 1 / Phase 2 | 43 | SpectraCure ABINDUSTRY | 2 | May 1, 2026 | clinicaltrials |
| NCT07562438 | Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06682728 | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence | recruiting | Phase 2 | 23 | University of California, IrvineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07241793 | Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)(TRAIN-UC-01) | recruiting | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07451795 | SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC(SHARP) | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06594926 | Working Out M0 Bipolar Androgen Therapy(WOMBAT) | recruiting | Phase 2 | 69 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03522064 | Bipolar Androgen Therapy + Carboplatin in mCRPC(HiTeCH) | recruiting | Phase 2 | 30 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06157151 | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 2 | 24 | Precigen, IncINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06180356 | Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression(ANALLISA) | recruiting | Phase 2 | 30 | MedSIROTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06769152 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors | recruiting | Phase 2 | 190 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT04946370 | Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 52 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07303387 | Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.(EZHiSWITCH) | recruiting | Phase 2 | 900 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07407283 | A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07407647 | Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer | recruiting | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07340164 | Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy(TROY) | recruiting | Phase 2 | 116 | Yonsei UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07322263 | Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC | recruiting | Phase 2 | 174 | Michael A. O'DonnellOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05123807 | Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06347705 | A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer | recruiting | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05559879 | Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma | recruiting | Phase 1 / Phase 2 | 37 | University of Alabama at BirminghamOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06615752 | Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients | recruiting | Phase 1 / Phase 2 | 99 | Charles Drew University of Medicine and ScienceOTHER | 1 | Apr 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 19, 2026source: clinicaltrials